Compare ECX & LXRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ECX | LXRX |
|---|---|---|
| Founded | 2017 | 1995 |
| Country | China | United States |
| Employees | 1918 | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 560.1M | 547.4M |
| IPO Year | N/A | 2000 |
| Metric | ECX | LXRX |
|---|---|---|
| Price | $1.15 | $1.70 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $4.15 |
| AVG Volume (30 Days) | ★ 6.0M | 2.3M |
| Earning Date | 01-01-0001 | 06-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 77.78 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $49,803,000.00 |
| Revenue This Year | $819.09 | N/A |
| Revenue Next Year | $32.36 | $22.16 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 60.24 |
| 52 Week Low | $0.76 | $0.32 |
| 52 Week High | $3.07 | $1.83 |
| Indicator | ECX | LXRX |
|---|---|---|
| Relative Strength Index (RSI) | 32.42 | 63.28 |
| Support Level | N/A | $1.08 |
| Resistance Level | $1.79 | $1.83 |
| Average True Range (ATR) | 0.21 | 0.12 |
| MACD | -0.04 | 0.02 |
| Stochastic Oscillator | 5.63 | 75.34 |
ECARX Holdings Inc is engaged in the sales of system-on-chip core modules, automotive computing platform products, and software stacks as well as the provision of research and development services in the People's Republic of China. The company's core products include infotainment head units, digital cockpits, vehicle chip-set solutions, a core operating system, and an integrated software stack. Beyond this, ECARX is developing a full-stack automotive computing platform. It is engaged in automotive intelligence and networking.
Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, also developing LX9851, an orally-delivered small molecule drug candidate, as a treatment for obesity and associated cardiometabolic.